Zhengru Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhengru Shen has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Marco Spruit
Leiden University
4 shared publications - Anne Spinewine
Clinical Pharmacy and Pharmacoepidemiology Research Group (CLIP), Louvain Drug Research Institute (LDRI), UCLouvain, Brussels, Belgium
1 shared publication - Axel Löwe
Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
1 shared publication - Bastiaan Theodoor Gerard Marie Sallevelt
Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
1 shared publication - Benoit Boland
Cliniques Universitaires Saint-Luc
1 shared publication - Corlina Johanna Alida Huibers
Department of Geriatric Medicine, University Medical Centre Utrecht, Utrecht University, 3508 TC Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 17 March 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (6) , 2663
Automatic Extraction of Adverse Drug Reactions from Summary of Product Characteristics
The summary of product characteristics from the European Medicines Agency is a reference document on medicines in the EU. It contains textual information for clinical experts on how to safely use medicines, including adverse drug reactions. Using natural language processing (NLP) techniques to automatically extract adverse drug reactions from such unstructured textual information helps clinical experts to effectively and efficiently use them in daily practices. Such techniques have been developed for Structured Product Labels from the Food and Drug Administration (FDA), but there is no research focusing on extracting from the Summary of Product Characteristics. In this work, we built a natural language processing pipeline that automatically scrapes the summary of product characteristics online and then extracts adverse drug reactions from them. Besides, we have made the method and its output publicly available so that it can be reused and further evaluated in clinical practices. In total, we extracted 32,797 common adverse drug reactions for 647 common medicines scraped from the Electronic Medicines Compendium. A manual review of 37 commonly used medicines has indicated a good performance, with a recall and precision of 0.99 and 0.934, respectively.
- 17 March 2021
- Published by MDPI AG in Applied Sciences
- Vol. 11 (6) , 2663
Open AccessAutomatic Extraction of Adverse Drug Reactions from Summary of Product Characteristics
The summary of product characteristics from the European Medicines Agency is a reference document on medicines in the EU. It contains textual information for clinical experts on how to safely use medicines, including adverse drug reactions. Using natural language processing (NLP) techniques to automatically extract adverse drug reactions from such unstructured textual information helps clinical experts to effectively and efficiently use them in daily practices. Such techniques have been developed for Structured Product Labels from the Food and Drug Administration (FDA), but there is no research focusing on extracting from the Summary of Product Characteristics. In this work, we built a natural language processing pipeline that automatically scrapes the summary of product characteristics online and then extracts adverse drug reactions from them. Besides, we have made the method and its output publicly available so that it can be reused and further evaluated in clinical practices. In total, we extracted 32,797 common adverse drug reactions for 647 common medicines scraped from the Electronic Medicines Compendium. A manual review of 37 commonly used medicines has indicated a good performance, with a recall and precision of 0.99 and 0.934, respectively.
- Open Access
- 17 March 2020
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-12
Intervention protocol: OPtimising thERapy to prevent avoidable hospital Admission in the Multi-morbid elderly (OPERAM): a structured medication review with support of a computerised decision support system
Background: Several approaches to medication optimisation by identifying drug-related problems in older people have been described. Although some interventions have shown reductions in drug-related problems (DRPs), evidence supporting the effectiveness of medication reviews on clinical and economic outcomes is lacking. Application of the STOPP/START (version 2) explicit screening tool for inappropriate prescribing has decreased inappropriate prescribing and significantly reduced adverse drug reactions (ADRs) and associated healthcare costs in older patients with multi-morbidity and polypharmacy. Therefore, application of STOPP/START criteria during a medication review is likely to be beneficial.Incorporation of explicit screening tools into clinical decision support systems (CDSS) has gained traction as a means to improve both quality and efficiency in the rather time-consuming medication review process. Although CDSS can generate more potential inappropriate medication recommendations, some of these have been shown to be less clinically relevant, resulting in alert fatigue. Moreover, explicit tools such as STOPP/START do not cover all relevant DRPs on an individual patient level. The OPERAM study aims to assess the impact of a structured drug review on the quality of pharmacotherapy in older people with multi-morbidity and polypharmacy. The aim of this paper is to describe the structured, multi-component intervention of the OPERAM trial and compare it with the approach in the comparator arm.Method: This paper describes a multi-component intervention, integrating interventions that have demonstrated effectiveness in defining DRPs. The intervention involves a structured history-taking of medication (SHiM), a medication review according to the systemic tool to reduce inappropriate prescribing (STRIP) method, assisted by a clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2), followed by shared decision-making with both patient and attending physician. The developed method integrates patient input, patient data, involvement from other healthcare professionals and CDSS-assistance into one structured intervention.Discussion: The clinical and economical effectiveness of this experimental intervention will be evaluated in a cohort of hospitalised, older patients with multi-morbidity and polypharmacy in the multicentre, randomized controlled OPERAM trial (OPtimising thERapy to prevent Avoidable hospital admissions in the Multi-morbid elderly), which will be completed in the last quarter of 2019.Trial registration: Universal Trial Number:U1111-1181-9400Clinicaltrials.gov:NCT02986425, Registered 08 December 2016.FOPH (Swiss national portal):SNCTP000002183. Netherlands Trial Register:NTR6012(07-10-2016).
- 17 March 2020
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-12
Open AccessIntervention protocol: OPtimising thERapy to prevent avoidable hospital Admission in the Multi-morbid elderly (OPERAM): a structured medication review with support of a computerised decision support system
Background: Several approaches to medication optimisation by identifying drug-related problems in older people have been described. Although some interventions have shown reductions in drug-related problems (DRPs), evidence supporting the effectiveness of medication reviews on clinical and economic outcomes is lacking. Application of the STOPP/START (version 2) explicit screening tool for inappropriate prescribing has decreased inappropriate prescribing and significantly reduced adverse drug reactions (ADRs) and associated healthcare costs in older patients with multi-morbidity and polypharmacy. Therefore, application of STOPP/START criteria during a medication review is likely to be beneficial.Incorporation of explicit screening tools into clinical decision support systems (CDSS) has gained traction as a means to improve both quality and efficiency in the rather time-consuming medication review process. Although CDSS can generate more potential inappropriate medication recommendations, some of these have been shown to be less clinically relevant, resulting in alert fatigue. Moreover, explicit tools such as STOPP/START do not cover all relevant DRPs on an individual patient level. The OPERAM study aims to assess the impact of a structured drug review on the quality of pharmacotherapy in older people with multi-morbidity and polypharmacy. The aim of this paper is to describe the structured, multi-component intervention of the OPERAM trial and compare it with the approach in the comparator arm.Method: This paper describes a multi-component intervention, integrating interventions that have demonstrated effectiveness in defining DRPs. The intervention involves a structured history-taking of medication (SHiM), a medication review according to the systemic tool to reduce inappropriate prescribing (STRIP) method, assisted by a clinical decision support system (STRIP Assistant, STRIPA) with integrated STOPP/START criteria (version 2), followed by shared decision-making with both patient and attending physician. The developed method integrates patient input, patient data, involvement from other healthcare professionals and CDSS-assistance into one structured intervention.Discussion: The clinical and economical effectiveness of this experimental intervention will be evaluated in a cohort of hospitalised, older patients with multi-morbidity and polypharmacy in the multicentre, randomized controlled OPERAM trial (OPtimising thERapy to prevent Avoidable hospital admissions in the Multi-morbid elderly), which will be completed in the last quarter of 2019.Trial registration: Universal Trial Number:U1111-1181-9400Clinicaltrials.gov:NCT02986425, Registered 08 December 2016.FOPH (Swiss national portal):SNCTP000002183. Netherlands Trial Register:NTR6012(07-10-2016).
- Open Access
- 15 August 2019
- Published by Wiley in Journal of Healthcare Engineering
- Vol. 2019, 1-11
A Lightweight API-Based Approach for Building Flexible Clinical NLP Systems
Natural language processing (NLP) has become essential for secondary use of clinical data. Over the last two decades, many clinical NLP systems were developed in both academia and industry. However, nearly all existing systems are restricted to specific clinical settings mainly because they were developed for and tested with specific datasets, and they often fail to scale up. Therefore, using existing NLP systems for one’s own clinical purposes requires substantial resources and long-term time commitments for customization and testing. Moreover, the maintenance is also troublesome and time-consuming. This research presents a lightweight approach for building clinical NLP systems with limited resources. Following the design science research approach, we propose a lightweight architecture which is designed to be composable, extensible, and configurable. It takes NLP as an external component which can be accessed independently and orchestrated in a pipeline via web APIs. To validate its feasibility, we developed a web-based prototype for clinical concept extraction with six well-known NLP APIs and evaluated it on three clinical datasets. In comparison with available benchmarks for the datasets, three high F1 scores (0.861, 0.724, and 0.805) were obtained from the evaluation. It also gained a low F1 score (0.373) on one of the tests, which probably is due to the small size of the test dataset. The development and evaluation of the prototype demonstrates that our approach has a great potential for building effective clinical NLP systems with limited resources.
- 15 August 2019
- Published by Wiley in Journal of Healthcare Engineering
- Vol. 2019, 1-11
Open AccessA Lightweight API-Based Approach for Building Flexible Clinical NLP Systems
Natural language processing (NLP) has become essential for secondary use of clinical data. Over the last two decades, many clinical NLP systems were developed in both academia and industry. However, nearly all existing systems are restricted to specific clinical settings mainly because they were developed for and tested with specific datasets, and they often fail to scale up. Therefore, using existing NLP systems for one’s own clinical purposes requires substantial resources and long-term time commitments for customization and testing. Moreover, the maintenance is also troublesome and time-consuming. This research presents a lightweight approach for building clinical NLP systems with limited resources. Following the design science research approach, we propose a lightweight architecture which is designed to be composable, extensible, and configurable. It takes NLP as an external component which can be accessed independently and orchestrated in a pipeline via web APIs. To validate its feasibility, we developed a web-based prototype for clinical concept extraction with six well-known NLP APIs and evaluated it on three clinical datasets. In comparison with available benchmarks for the datasets, three high F1 scores (0.861, 0.724, and 0.805) were obtained from the evaluation. It also gained a low F1 score (0.373) on one of the tests, which probably is due to the small size of the test dataset. The development and evaluation of the prototype demonstrates that our approach has a great potential for building effective clinical NLP systems with limited resources.
- Open Access
- 3 January 2019
- Published by MDPI AG in Applied Sciences
- Vol. 9 (1) , 150
A Systematic Review of Open Source Clinical Software on GitHub for Improving Software Reuse in Smart Healthcare
The plethora of open source clinical software offers great reuse opportunities for developers to build clinical tools at lower cost and at a faster pace. However, the lack of research on open source clinical software poses a challenge for software reuse in clinical software development. This paper aims to help clinical developers better understand open source clinical software by conducting a thorough investigation of open source clinical software hosted on GitHub. We first developed a data pipeline that automatically collected and preprocessed GitHub data. Then, a deep analysis with several methods, such as statistical analysis, hypothesis testing, and topic modeling, was conducted to reveal the overall status and various characteristics of open source clinical software. There were 14,971 clinical-related GitHub repositories created during the last 10 years, with an average annual growth rate of 55%. Among them, 12,919 are open source clinical software. Our analysis unveiled a number of interesting findings: Popular open source clinical software in terms of the number of stars, most productive countries that contribute to the community, important factors that make an open source clinical software popular, and 10 main groups of open source clinical software. The results can assist both researchers and practitioners, especially newcomers, in understanding open source clinical software.
- 3 January 2019
- Published by MDPI AG in Applied Sciences
- Vol. 9 (1) , 150
Open AccessA Systematic Review of Open Source Clinical Software on GitHub for Improving Software Reuse in Smart Healthcare
The plethora of open source clinical software offers great reuse opportunities for developers to build clinical tools at lower cost and at a faster pace. However, the lack of research on open source clinical software poses a challenge for software reuse in clinical software development. This paper aims to help clinical developers better understand open source clinical software by conducting a thorough investigation of open source clinical software hosted on GitHub. We first developed a data pipeline that automatically collected and preprocessed GitHub data. Then, a deep analysis with several methods, such as statistical analysis, hypothesis testing, and topic modeling, was conducted to reveal the overall status and various characteristics of open source clinical software. There were 14,971 clinical-related GitHub repositories created during the last 10 years, with an average annual growth rate of 55%. Among them, 12,919 are open source clinical software. Our analysis unveiled a number of interesting findings: Popular open source clinical software in terms of the number of stars, most productive countries that contribute to the community, important factors that make an open source clinical software popular, and 10 main groups of open source clinical software. The results can assist both researchers and practitioners, especially newcomers, in understanding open source clinical software.